Physician profile
Nat E Levinson
NPI 1942288212
$5,216.62
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,699 · 2020: $142 · 2021: $250 · 2022: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $4,388.27 | 2019 | |
| Glaxosmithkline, LLC. | $250.00 | 2021 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $121.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $46.32 | 2019 | |
| Mylan Specialty L.P. | $17.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.29 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nat Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.